Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $689.93 Consensus Price Target from Analysts

Posted by Stanley Muller on Aug 9th, 2026

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eighteen analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and fifteen have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $689.9333.

A number of equities research analysts have issued reports on MDGL shares. Wells Fargo & Company assumed coverage on shares of Madrigal Pharmaceuticals in a report on Monday, July 27th. They set an “overweight” rating and a $685.00 target price on the stock. Bank of America dropped their price target on shares of Madrigal Pharmaceuticals from $550.00 to $542.00 and set a “neutral” rating for the company in a research note on Thursday, June 11th. HC Wainwright reaffirmed a “buy” rating on shares of Madrigal Pharmaceuticals in a research report on Friday, July 31st. Citigroup reaffirmed an “outperform” rating on shares of Madrigal Pharmaceuticals in a research report on Friday, July 17th. Finally, Canaccord Genuity Group increased their price objective on Madrigal Pharmaceuticals from $578.00 to $587.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th.

View Our Latest Analysis on Madrigal Pharmaceuticals

Insider Activity

In other news, insider David Soergel sold 1,042 shares of Madrigal Pharmaceuticals stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $495.74, for a total value of $516,561.08. Following the completion of the transaction, the insider owned 10,033 shares in the company, valued at approximately $4,973,759.42. This trade represents a 9.41% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard S. Levy sold 5,682 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $515.44, for a total value of $2,928,730.08. Following the transaction, the director directly owned 22,015 shares of the company’s stock, valued at approximately $11,347,411.60. This represents a 20.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,568 shares of company stock valued at $3,880,711 in the last quarter. Company insiders own 17.60% of the company’s stock.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

A number of large investors have recently modified their holdings of MDGL. Flagship Harbor Advisors LLC purchased a new stake in Madrigal Pharmaceuticals during the 4th quarter worth about $29,000. Persistent Asset Partners Ltd acquired a new position in shares of Madrigal Pharmaceuticals in the 2nd quarter valued at $29,000. Global Retirement Partners LLC purchased a new stake in shares of Madrigal Pharmaceuticals in the second quarter valued at about $34,000. Kemnay Advisory Services Inc. acquired a new position in Madrigal Pharmaceuticals in the 4th quarter valued at about $39,000. Finally, Quarry LP acquired a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at about $39,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

Madrigal Pharmaceuticals Stock Down 0.1%

Shares of NASDAQ:MDGL opened at $510.04 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.20 and a quick ratio of 2.94. The firm has a market capitalization of $11.78 billion, a PE ratio of -39.57 and a beta of -1.01. The firm’s 50-day moving average is $515.31 and its two-hundred day moving average is $499.17. Madrigal Pharmaceuticals has a 1 year low of $339.31 and a 1 year high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.68) by $0.69. The business had revenue of $364.25 million for the quarter, compared to analysts’ expectations of $352.13 million. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. The business’s quarterly revenue was up 71.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.90) earnings per share. Analysts predict that Madrigal Pharmaceuticals will post -7.03 EPS for the current year.

About Madrigal Pharmaceuticals

(Get Free Report)

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.